Your session is about to expire
← Back to Search
Lonsurf for Bladder Cancer
Study Summary
This trial is testing a new cancer drug, TAS-102, to see if it helps people with urothelial carcinoma who haven't responded to other treatments.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have cancer that has spread to your brain.You have had allergic reactions to drugs similar to TAS 102.You must have a visible and measurable tumor that can be accurately measured.You have been diagnosed with advanced urinary bladder cancer, and the type of cancer cells in your biopsy is transitional cell carcinoma.You have a serious illness that is not under control, such as an ongoing infection or heart problems. If you are currently being treated for another type of cancer, you may not be eligible for the study.You have experienced worsening of your condition while taking a previous checkpoint inhibitor, or you are not allowed to take a checkpoint inhibitor.You have HIV and are taking specific medications for it.You have experienced disease progression within 12 months of receiving a specific type of chemotherapy.
- Group 1: Intervention TAS-102
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there any openings currently available for this trial?
"Evidenced by the clinicaltrials.gov page, this trial is actively in search of participants. This study has been live since March 1st 2019 and was recently updated on September 3rd 2022."
Does the FDA recognize TAS 102 as a legitimate pharmaceutical?
"TAS 102's safety is rated at 2 out of 3 due to the fact that there is no clinical data confirming its efficacy, but some studies have suggested it can be consumed safely."
What is the cap on participant numbers for this clinical experiment?
"Confirmed. As per the information disclosed on clinicaltrials.gov, this particular research endeavour has been recruiting since January 3rd 2019 and is actively searching for 22 participants at 2 distinct locations as of March 9th 2022."
Is this particular trial the pioneer of its genre?
"TAS 102 is currently the subject of 28 open clinical trials across 174 cities and 25 nations. Sponsored by Taiho Oncology, Inc., this drug was initiated for testing in 2017 with a Phase 1 & 2 trial including 56 participants. After 4 years, there have been 21 subsequent investigations conducted on TAS 102."
Is there a body of literature on the efficacy of TAS 102?
"Presently, there are 28 ongoing investigations into the efficacy of TAS 102 with two studies progressing to Phase 3. Although Buffalo holds many trials for this medication, its use is being studied at 333 different centres across America."
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger